Synthesis of 2-anilinopyridyl-triazole conjugates as antimitotic agents

Organic & Biomolecular Chemistry
Ahmed KamalVunnam Srinivasulu

Abstract

A series of 2-anilinopyridyl–triazole conjugates (6a–t) were prepared and evaluated for their cytotoxic activity against a panel of three human cancer cell lines. Among them compounds 6q, 6r and 6s showed significant cytotoxic activity with IC50 values ranging from 0.1 to 4.1 μM. Structure–activity relationships were elucidated with various substitutions on these conjugates. Flow cytometric analysis revealed that these compounds arrest the cell cycle at the G2/M phase and induce cell death by apoptosis. The tubulin polymerization assay and immunofluorescence analysis showed that these compounds (6q, 6r and 6s) effectively inhibited the microtubule assembly in human prostate cancer cells (DU-145). The docking studies showed that 6s interacts and binds efficiently with the tubulin protein at the colchicine binding site. This was further confirmed by the colchicine competitive binding assay. Moreover, compounds 6q, 6r and 6s possess anti-tubulin activity both in vitro and within cells as demonstrated by the ratio of soluble versus polymerized tubulin. Further the apoptotic effects of compounds were confirmed by Hoechst staining, caspase 3 activation, annexin-V FITC, mitochondrial membrane potential and DNA fragmentation analysis. ...Continue Reading

References

Jun 1, 1997·Molecular Biology of the Cell·R J VasquezL Cassimeris
Mar 4, 1998·Current Opinion in Cell Biology·K H Downing, E Nogales
Mar 4, 1998·Current Opinion in Cell Biology·M A Jordan, L Wilson
Jul 8, 1998·Cancer Chemotherapy and Pharmacology·K YamamotoH Niitani
Jul 17, 1998·Medicinal Research Reviews·A JordanA T McGown
Oct 3, 1999·Journal of Medicinal Chemistry·T OwaK Kitoh
Jan 30, 2002·Cellular and Molecular Life Sciences : CMLS·O ValironD Job
Apr 2, 2004·Nature Reviews. Cancer·Mary Ann Jordan, Leslie Wilson
Jun 16, 2004·Cancer·Dietmar W SiemannMichael R Horsman
Sep 24, 2004·Trends in Pharmacological Sciences·Olivier Feron
Jan 27, 2007·Bioorganic & Medicinal Chemistry Letters·Maurizio BottaEzio Bombardelli
Jan 19, 2008·Molecular Cancer Therapeutics·Kelly HuberStewart Martin
Apr 15, 2008·Biochemical and Biophysical Research Communications·Kazue GondaGoshi Shiota
Jun 4, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ann M MauerGary B Gordon
Apr 29, 2009·Journal of Computational Chemistry·Garrett M MorrisArthur J Olson
Apr 28, 2010·Journal of Medicinal Chemistry·Romeo RomagnoliGiampietro Viola
Oct 5, 2010·Bioorganic & Medicinal Chemistry Letters·Rosana CrespoRodolfo D Bravo
Apr 13, 2011·European Journal of Medicinal Chemistry·Ahmed KamalSistla Ramakrishna
May 1, 2012·Bioorganic & Medicinal Chemistry·Ahmed KamalAnthony Addlagatta

❮ Previous
Next ❯

Citations

Sep 9, 2015·Organic & Biomolecular Chemistry·T Srinivasa ReddyRavi Shukla
Oct 17, 2016·European Journal of Medicinal Chemistry·Siddiq Pasha ShaikAhmed Kamal
May 18, 2019·Organic & Biomolecular Chemistry·Iqubal SinghKamaldeep Paul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis